Epsilon M&A Deal Report - Xellia Group (Xellia Pharmaceuticals)
Transaction Multiples for the Valuation of Private Companies
Private Group led by Novo A/S / Xellia Group (Xellia Pharmaceuticals)
- Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Pharmaceuticals
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Biomedical Research Laboratory
EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
---|---|---|---|---|---|---|---|---|
Historic | ![]() |
![]() |
ns | |||||
Current |
![]() |
Multiple available |
n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Pharmaceuticals » = 129
- Number of EMAT Reports / sub-sector « Biomedical Research Laboratory » = 34
Date | Acquirer | Target | Country | Multiples | See details |
30/09/2013 | Aspen Pharmacare Holdings | Fraxiparine and Arixtra brands of GSK and Associated Manufacturing Plant | France | ** | 62935 |
22/05/2013 | Private Group led by Charterhouse Capital Partners LLP | DOC Generici | Italy | *** | 62906 |
Source: Epsilon Research / EMAT